Patents by Inventor Scott R. Presnell

Scott R. Presnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-23 antagonists
    Patent number: 8227579
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: July 24, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, James W. West, Robert Mabry, Brent Meengs, Steven D. Levin
  • ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME
    Publication number: 20120177653
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Application
    Filed: February 2, 2012
    Publication date: July 12, 2012
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Methods of treating inflammatory disease using a soluble IL-20 receptor
    Patent number: 8217008
    Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: July 10, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Donald C. Foster, Wenfeng Xu, Karen L. Madden, James D. Kelly, Cindy A. Sprecher, Cameron S. Brandt, Mark W. Rixon, Scott R. Presnell, Brian A. Fox
  • ANTI-IL-TIF ANTIBODIES AND METHODS OF USE
    Publication number: 20120156209
    Abstract: The present invention relates to ZCYTO18 polynucleotide and polypeptide molecules. The ZCYTO18 is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: January 3, 2012
    Publication date: June 21, 2012
    Applicant: ZYMOGENETICS, INC.
    Inventors: Scott R. PRESNELL, Wayne KINDSVOGEL
  • HUMAN CYTOKINE RECEPTOR
    Publication number: 20120082673
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Application
    Filed: November 3, 2011
    Publication date: April 5, 2012
    Inventors: Scott R. PRESNELL, Wenfeng XU, Wayne R. KINDSVOGEL, Zhi CHEN, Steven D. HUGHES
  • ZCYTOR19 POLYNUCLEOTIDES, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE
    Publication number: 20120064571
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: October 6, 2011
    Publication date: March 15, 2012
    Inventors: Scott R. Presnell, Francis J. Grant, Emily C. Costerison, Theodore E. Whitmore
  • Anti-IL-TIF antibodies and methods of making
    Patent number: 8124077
    Abstract: The present invention relates to ZCYTO18 polynucleotide and polypeptide molecules. The ZCYTO18 is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: February 28, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wayne Kindsvogel
  • INTERFERON-LIKE PROTEIN ZCYTO21
    Publication number: 20120036590
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
    Type: Application
    Filed: September 8, 2011
    Publication date: February 9, 2012
    Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant
  • Method of use of cytokine ZALPHA11 ligand
    Patent number: 8110180
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: February 7, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Methods for detecting modulators of cytokine receptor zalpha11
    Patent number: 8110372
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: February 7, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Darrell C. Conklin, Julia E. Novak, Angela K. Hammond
  • Human cytokine receptor
    Patent number: 8101381
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides polynucleotides, vectors, cells, and methods of production related to a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: January 24, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME
    Publication number: 20110318350
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Application
    Filed: August 5, 2011
    Publication date: December 29, 2011
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • NUCLEIC ACID ENCODING CYTOKINE RECEPTOR ZCYTOR17
    Publication number: 20110287012
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: April 20, 2011
    Publication date: November 24, 2011
    Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
  • Method of suppressing or reducing IL-TIF-induced inflammation, or treating associated conditions thereof, using Zcytor16
    Patent number: 8034784
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16” and uses thereof.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: October 11, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Cytokine zalpha11 ligand antibodies and methods of use
    Patent number: 8017343
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: September 13, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Cytokine zalpha11 ligand antibodies
    Patent number: 7998468
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 16, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • METHODS FOR SOLUBLE ZALPHA11 CYTOKINE RECEPTORS
    Publication number: 20110189207
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: February 4, 2011
    Publication date: August 4, 2011
    Inventors: Cindy A. Sprecher, Julia E. Novak, James W. West, Scott R. Presnell, Richard D. Holly, Andrew J. Nelson
  • METHODS FOR DETECTING MODULATORS OF CYTOKINE RECEPTOR ZALPHA11
    Publication number: 20110183359
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: March 3, 2011
    Publication date: July 28, 2011
    Inventors: Scott R. Presnell, Darrell C. Conklin, Julia E. Novak, Angela K. Hammond
  • COMPOSITIONS AND METHODS FOR INHIBITING PDGFRBETA AND VEGF-A
    Publication number: 20110177074
    Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.
    Type: Application
    Filed: March 27, 2009
    Publication date: July 21, 2011
    Inventors: Pallavur V. Sivakumar, Debra G. Gilbertson, Marshall D. Snavely, George R. Mabry, Eugene C. Yi, Yue Yao, Scott R. Presnell
  • SOLUBLE ZCYTOR14, ANTI-ZCYTOR14 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20110177083
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
    Type: Application
    Filed: January 27, 2011
    Publication date: July 21, 2011
    Applicant: Zymogenetics, Inc.
    Inventors: Scott R. Presnell, Steven K. Burkhead, Steven D. Levin, Rolf E. Kuestner, Zeren Gao, Stephen R. Jaspers, Janine Bilsborough